Oncology is evolving as new multimodal AI models fuse genetic, imaging, and clinical data into one cohesive map, shattering diagnostic limitations. These systems detect early-stage cancer with lethal precision, and the FDA’s 2026 approval marks a turning point. Clinical-grade hardware packing 12-core power is expected to hit hospitals this June, automating pattern recognition and empowering specialists to save more lives.